A new gene therapy approach for epilepsy tamps down neural activity on demand.

A massive update to the MSSNG dataset gives qualified researchers ready access to explore autism’s genetic architecture on a cloud-based platform.

The technique could be used to identify and control cells involved in autism.

A meeting in Texas reckons with the future of treatment, following two setbacks in 2020.

The technique involves editing the cellular instructions to make MECP2 protein and partially restores its levels in the brainstem.

Roche’s gene therapy drug Rugonersen boosts expression of the protein missing in the syndrome in mice and monkeys, but whether it works in people remains to be seen.

Interim results from the previously paused trial suggest that doses of the experimental gene therapy drug GTX-102 are well tolerated in children with the autism-linked condition.

A handful of scientists are committed to advancing research on the autism-related genetic conditions their own children have.

The approach, tested in mice, selectively boosts the expression of the autism-linked gene SCN1A in a subgroup of inhibitory cells.

Strategies to replace or compensate for mutated copies of the TCF4 gene could lead to treatments for this profound form of autism, a new study suggests.